Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of alginate sulfuric ester in preparing drugs for preventing and treating diabetes and vascular diseases

A technology for diabetic blood vessels and fucoidan is applied in the application field of fucoidan sulfate in the preparation of drugs for preventing and treating diabetic vascular diseases, and can solve the problems of not achieving ideal effects, few drugs for diabetic vascular diseases, unclear diabetes mechanism, and the like, Achieve significant curative effect, less side effects, and reduce diabetic hypertension

Active Publication Date: 2013-03-20
CAPITAL UNIVERSITY OF MEDICAL SCIENCES
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Due to the unclear mechanisms leading to various lesions in diabetes, there are very few clinically available drugs for the treatment of diabetic vascular lesions
Angiotensin receptor blockers are effective, but far from ideal

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of alginate sulfuric ester in preparing drugs for preventing and treating diabetes and vascular diseases
  • Application of alginate sulfuric ester in preparing drugs for preventing and treating diabetes and vascular diseases
  • Application of alginate sulfuric ester in preparing drugs for preventing and treating diabetes and vascular diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0041] Embodiment 1, the therapeutic effect of fucoidan sulfate on the vascular disease of type I diabetes model rats

[0042] 1) Model building and grouping

[0043] Type I diabetes is the most typical and the most serious type of diabetes. Therefore, the type I diabetes model was selected in this experiment to study whether fucoidan (Fucoidan, hereinafter referred to as F) has a preventive effect on the change of diabetic vascular function and structure and its mechanism.

[0044] Sprague-Dawley (SD) male rats with a body weight of 160-180 g were selected for the experiment. The experiment is divided into normal control group (Con), diabetes group (Diabetes), diabetic intraperitoneal administration of low dose F (50mg / kg / Day) (FL) and high dose F (100mg / kg / Day) (FH) groups, and Fenofibrate (Fenofibrate, 100mg / kg / Day) control drug group, the drug is clinically used for the treatment of hyperlipidemia by inhibiting oxidative stress. The type I diabetes model was made with st...

Embodiment 2

[0057] Example 2. Study on Vascular Reactivity of Fucoidan Sulfate to Type I Diabetes Model Rats

[0058] The establishment and grouping of the model are the same as in Example 1.

[0059] 1) Measure the dose-effect relationship of the endothelialized thoracic aortic rings and tail artery rings to the constrictor phenylephrine (PE) in the experimental rats in the 4th and 12th weeks of modeling, and weigh the rings at the same time . The specific experimental results are shown in Table 3. figure 1 , figure 2 .

[0060] Table 3 Fucoidan sulfate on the effect of endothelialized thoracic aortic rings in diabetic rats

[0061] and tail artery ring on the response to phenylephrine (n = 4 ~ 8)

[0062]

[0063] From the results in Table 3, it can be seen that the aorta and tail artery of the diabetic group exhibited hyperresponsiveness of contraction to phenylephrine stimulation. Tail artery improvement was statistically significant.

[0064] 2) In order ...

Embodiment 3

[0071] Example 3. Research on the related mechanism of fucoidan sulfate on the vascular reactivity of type I diabetes model rats

[0072] The establishment and grouping of the model are the same as in Example 1.

[0073] Determination of the oxidoreductase activity of rat aortic smooth muscle in the 12th week, including SOD, GSH, etc., see the results image 3 and Figure 4 ; The expression level of cyclooxygenase in aortic smooth muscle, the results are shown in Figure 5 and 6 ;HE staining of blood vessel cross-section to observe the change of microstructure and the therapeutic effect of the drug to be tested, the results are shown in Figure 7 .

[0074] 1) by image 3 and Figure 4 It can be seen that the activity of reductase related to oxidative stress pathway measured by the total protein extract of aortic smooth muscle administered for 12 weeks showed that the activity of reductase related to diabetic vascular smooth muscle decreased, fucoidan sulfate can increas...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a new application of an alginate sulfuric ester, which is the application of the alginate sulfuric ester in preparing drugs for preventing and treating diabetes and vascular diseases. The alginate sulfuric ester optimizes low molecular weight alginate with the weight-average molecular weight of 3-30 KD and comprises the following materials in percentage by weight: 25%-35% of fucose and 25%-35% of sulfate; and the low molecular weight alginate sulfuric ester is obtained by degrading alginate sulfuric ester. Shown by I type diabetes model rat in vivo animal experiments, in vitro tissue experiments and protein level research, the alginate sulfuric ester has certain therapeutic action on the diabetes and vascular complications, and the mechanism of the alginate sulfuric ester is related to the effects of reducing the oxidative stress level of the diabetes and the epoxidase-2 expression of vascular smooth muscles so as to influence the forming of prostaglandins substances.

Description

technical field [0001] The invention relates to the application of fucoidan sulfate in the preparation of drugs for preventing and treating diabetic vascular diseases. Background technique [0002] Fucoidan sulfate is a kind of natural sulfated polysaccharide rich in fucose. It is currently reported that the substance has a variety of biological functions, such as anti-oxidation, anti-coagulation, anti-thrombosis, anti-proliferation, anti-adhesion, anti-viral effects and so on. [0003] Sulfated fucan polysaccharides (Fucans) are a class of anionic polysaccharides derived from marine organisms, most of which are derived from brown algae. Due to the different growth environments, regions, and species of algae, they show a variety of structures, but have a basic conservative structure. Fucoidan is the first polysaccharide isolated and extracted from sulfated Fucus. In 1913, Kylin was first obtained and named from brown algae. In the following decades, the extraction process ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/737A61P3/10A61P9/00A61P9/12A23L1/09A23L33/125
Inventor 罗大力任爽朱志翔张全斌
Owner CAPITAL UNIVERSITY OF MEDICAL SCIENCES
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com